A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs INCMGA 0012 (Primary)
- Indications Anal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms POD1UM-202
- Sponsors Incyte Corporation
- 12 Apr 2019 Planned End Date changed from 1 Dec 2023 to 1 Dec 2021.
- 10 Apr 2019 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2020.
- 18 Sep 2018 Status changed from not yet recruiting to recruiting.